
    
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel dose cohort,
      multiple dose study to evaluate the efficacy, safety, and tolerability of different doses of
      PB-119 to patients with T2DM not well-controlled by metformin monotherapy. Patients will be
      assessed for eligibility over a 2 week screening period prior to a 4-week run-in period and a
      12-week double-blind treatment period.A phase 2, multicenter, randomized, double-blind,
      placebo-controlled, parallel dose cohort study to evaluate the efficacy and safety of twelve
      once weekly subcutaneous doses of PB-119 to patients with type 2 diabetes mellitus (T2DM) not
      well-controlled by metformin monotherapy The eligible patients will be randomized to 1 of 3
      dose cohorts (A, B, or C). Each patient will subsequently be randomized within the designated
      cohort to 1) active drug or placebo at a 3:1 active drug:placebo ratio and 2) exclusion from
      or inclusion in the pharmacokinetic (PK) blood sample collection subgroup at a 3:1
      excluded:included ratio
    
  